Hematide™ for the treatment of chronic kidney disease-related anemia

Expert Review of Hematology

Volumn 2, Issue 4, 2009, Pages 377-383

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agents; Erythropoietin; Hematide

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MACROGOL; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEATH; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHROPOIESIS; FLUSHING; HUMAN; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; SIDE EFFECT; THROAT IRRITATION; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; PEPTIDES; POLYETHYLENE GLYCOLS;

EID: 77953404537     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.15     Document Type: Review

References (25)

1. Storring PL, Tiplady RJ, Gaines Das RE et al. Epoetin α and β differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. 100, 79-89 (1998).
2. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 64(5), 499-509 (2004).
3. Egrie JC, Browne KJ. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 16(Suppl. 3), 3-13 (2001).
4. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-β determined by surface plasmon resonance and competition binding assay. Pharmacology 81(1), 63-69 (2008).
5. Wrighton NC, Farrell FX, Chang R et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273(5274), 458-464 (1996).
6. Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273(5274), 464-471 (1996).
7. Fan Q, Leuther KK, Holmes CP et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp. Hematol. 34(10), 1303-1311 (2006).
8. Woodburn KW, Fan Q, Leuther KK et al. Preclinical evaluation of hematide, a novel erythropoietic receptor agonist for treatment of anemia caused by kidney disease. Blood 104(11), (2004) (Abstract 2904).
9. Woodburn KW, Leuther K, Holmes C et al. Renal excretion is the primary route of elimination for the erythropoiesis stimulating agent hematide as assessed by quantitative whole-body autoradioluminigraphy in Sprague Dawley rats. Nephrol. Dial. Tranplant. 22(Suppl. 6), (2007) (Abstract SAP333).
10. Woodburn KW, Schatz PJ, Fong KL, Ferrel T. Erythropoiesis equivalence, pharmacokinetics and antibody analysis following subcutaneous and intravenous administration in cynomolgus monkeys. J. Am. Soc. Nephrol. 17, (2006) (Abstract TH PO359).
11. Woodburn KW, Wilson SD, Fong KL et al. Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 93(9), 1376-1379 (2008).
12. Woodburn KW, Winslow S, Leuther KK et al. Hematide, a peptidic erythropoieisis stimulating agent that corrects anemia induced by partial nephrectomy and erythropoietin-specific antibodies in rats. Haematologica 93(Suppl 1), (2008) (Abstract 0469).
13. Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, Norton D. Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin. Pharmacol. Toxicol. 104(2), 155-163 (2009).
14. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108(6), 1830-1834 (2006).
15. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol. 48(1), 43-52 (2008).
16. Komura E, Umeda Y, Matsuno et al. Evaluation of the safety, pharmacokinetics and pharmacodynamics of Hematide™, a novel erythropoiesis stimulating agent, in a phase 1, single-blind, placebo-controlled, dose escalation study in Japanese healthy volunteers. J. Am. Soc. Nephrol. 22(Suppl. 6), (2007) (Abstract SAPO2666).
17. Duliege AM, Macdougall IC, Goldsmith D et al. Hematide (TM), a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in single dose studies in normal healthy volunteers (HV) and in patients with chronic kidney disease (CKD). Nephrol. Dial. Transplant. 21(Suppl. 4), (2006) (Abstract SP420).
18. Wiecek A, Tucker B, Nowicki M et al. Comparison of monthly dosing schemes using Hematide TM, a synthetic peptide-based erythropoiesis stimulating agent (ESA), to correct anemia in patients with chronic kidney disease (CKD) not on dialysis J. Am. Soc. Nephrol. 18, (2007) (Abstract SU-PO777).
19. Besarab A, Zeig S, Geronemus R et al. Comparison of monthly dosing schemes using hematide™, a synthetic peptidebased erythropoiesis stimulating agent (ESA), to maintain hemoglobin (Hb) in hemodialysis (HD) patients previously treated with epoetin alfa (EPO). J. Am. Soc. Nephrol. 18, (2007) (Abstract SU-PO783).
20. Zeig S, Geronemus R, Pergola P et al. AFX01-03 Hematide Study Group. Hematide maintains hemoglobin levels in dialysis patients irrespective gender, age, race or diabetes as a cause of CKD. J. Am. Soc. Nephrol. 19, (2008) (Abstract TH-PO726).
21. Covic A, Ardelean L, Manuelyan L et al. A Phase 2, open-label, multi-center, dose finding study of the safety, pharmacodynamics, and pharmacokinetics of hematide™ for the maintenance of anaemia in haemodialysis patients previously treated with epoetin. Nephrol. Dial. Transplant. 1(Suppl. 2), (2008) (Abstract MP390).
22. Macdougall I, Geronemus R, Ardelean L et al. AFX01-10 Hematide Study Group. Interim evaluation of long-term safety and tolerability of hematide™ during maintenance treatment in anemia in patients with chronic kidney disease on hemodialysis and not on hemodialysis. J. Am. Soc. Nephrol. 19, (2008) (Abstract TH-PO755).
23. Pergola P, Geronemus R, Zeig S et al. AFX01-03, 07, 09 and 10 Hematide Study Group. Once monthly Hematide TM maintains Hb in HD patients regardless of baseline iron and CRP status. Adv. Chronic Kidney Dis. 16(2), 152 (2009).
24. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp. Hematol. 35(8), 1201-1208 (2007).
25. Eckardt KE, Macdougall IC, Frissart M et al. Successful treatment of antierythropoietin antibody-mediated pure red cell aplasia with hematide™. Nephrol. Dial. Transplant. 1(Suppl. 2), (2008) (Abstract MO016).